- Home
- ALDX vs OFS Comparison
ALDX vs OFS Comparison
Compare ALDX & OFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- OFS
- Stock Information
- Founded
- ALDX 2004
- OFS 2001
- Country
- ALDX United States
- OFS United States
- Employees
- ALDX N/A
- OFS N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- OFS Finance/Investors Services
- Sector
- ALDX Health Care
- OFS Finance
- Exchange
- ALDX Nasdaq
- OFS Nasdaq
- Market Cap
- ALDX 133.7M
- OFS 110.3M
- IPO Year
- ALDX 2014
- OFS 2012
- Fundamental
- Price
- ALDX $2.24
- OFS $8.50
- Analyst Decision
- ALDX Strong Buy
- OFS
- Analyst Count
- ALDX 2
- OFS 0
- Target Price
- ALDX $9.50
- OFS N/A
- AVG Volume (30 Days)
- ALDX 1.5M
- OFS 44.4K
- Earning Date
- ALDX 05-20-2025
- OFS 05-01-2025
- Dividend Yield
- ALDX N/A
- OFS 15.91%
- EPS Growth
- ALDX N/A
- OFS N/A
- EPS
- ALDX N/A
- OFS 2.25
- Revenue
- ALDX N/A
- OFS $44,026,000.00
- Revenue This Year
- ALDX N/A
- OFS N/A
- Revenue Next Year
- ALDX N/A
- OFS N/A
- P/E Ratio
- ALDX N/A
- OFS $3.79
- Revenue Growth
- ALDX N/A
- OFS N/A
- 52 Week Low
- ALDX $1.14
- OFS $7.75
- 52 Week High
- ALDX $7.20
- OFS $10.04
- Technical
- Relative Strength Index (RSI)
- ALDX 36.53
- OFS 48.00
- Support Level
- ALDX $1.90
- OFS $8.68
- Resistance Level
- ALDX $2.89
- OFS $8.92
- Average True Range (ATR)
- ALDX 0.22
- OFS 0.31
- MACD
- ALDX 0.09
- OFS -0.00
- Stochastic Oscillator
- ALDX 33.46
- OFS 24.79
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.